Outlook Therapeutics
OTLK
20 hedge funds and large institutions have $2.17M invested in Outlook Therapeutics in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, reducing their positions, and 8 closing their positions.
0.52% less ownership
Funds ownership: 0.59% → 0.07% (-0.52%)
9% less funds holding
Funds holding: 22 → 20 (-2)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
40% less capital invested
Capital invested by funds: $3.6M → $2.17M (-$1.43M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
LVW Advisors
Pittsford,
New York
|
+$213K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$46.6K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$44.6K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$38.4K |
| 5 |
Squarepoint
New York
|
+$14.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.94M |
| 2 |
AC
Armistice Capital
New York
|
-$849K |
| 3 |
DI
DFPG Investments
Sandy,
Utah
|
-$25K |
| 4 |
BRWM
B. Riley Wealth Management
Memphis,
Tennessee
|
-$24K |
| 5 |
Barclays
London,
United Kingdom
|
-$21K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$1K | -42 | Closed |
|
27
Wells Fargo
San Francisco,
California
| – | +$71 | +4 | +57% |
|
OTLK Hedge Fund Activity: Q2 2020 in Review
20 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2020, worth a combined $2.17M — down 40% from $3.6M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of OTLK and 6 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 10 added.
The largest buyer was LVW Advisors, adding an estimated $213K. The largest seller was Sabby Management, exiting entirely with an estimated $1.94M sold.
- 20 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2020, down from 22 in Q1 2020.
- Funds reported $2.17M of Outlook Therapeutics stock for Q2 2020, down 40% quarter-over-quarter.
- 6 funds opened new Outlook Therapeutics positions in Q2 2020 and 8 closed out, a net change of -2 holders.
- The largest Outlook Therapeutics buyer in Q2 2020 was LVW Advisors, an estimated $213K added.
- The largest Outlook Therapeutics seller in Q2 2020 was Sabby Management, an estimated $1.94M sold.
Based on aggregated 13F filings for Q2 2020.